Rozrolimupab is a recombinant polyclonal antibody consisting of 25 different anti-Rhesus D (RhD) antibodies to replace existing anti-RhD hyperimmune immunoglobulins for the treatment of Idiopathic Thrombocytopenic Purpura (ITP) and the prevention of Hemolytic Disease of Newborns (HDN).
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Rozrolimupab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Rozrolimupab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Rozrolimupab. |
| Estrone | Estrone may increase the thrombogenic activities of Rozrolimupab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Rozrolimupab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Rozrolimupab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Rozrolimupab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Rozrolimupab. |
| Estriol | Estriol may increase the thrombogenic activities of Rozrolimupab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Rozrolimupab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Rozrolimupab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Rozrolimupab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Rozrolimupab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Rozrolimupab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Rozrolimupab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Rozrolimupab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Rozrolimupab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Rozrolimupab. |
| Equol | Equol may increase the thrombogenic activities of Rozrolimupab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Rozrolimupab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Rozrolimupab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Rozrolimupab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Rozrolimupab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Rozrolimupab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Rozrolimupab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Rozrolimupab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Rozrolimupab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Rozrolimupab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Rozrolimupab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Rozrolimupab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Rozrolimupab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Rozrolimupab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Rozrolimupab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Rozrolimupab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Rozrolimupab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Rozrolimupab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Rozrolimupab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Rozrolimupab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Rozrolimupab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Rozrolimupab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Rozrolimupab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Rozrolimupab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Rozrolimupab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Rozrolimupab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Rozrolimupab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Rozrolimupab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Rozrolimupab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Rozrolimupab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Rozrolimupab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Rozrolimupab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Rozrolimupab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Rozrolimupab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Rozrolimupab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Rozrolimupab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Rozrolimupab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Rozrolimupab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Rozrolimupab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Rozrolimupab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Rozrolimupab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Rozrolimupab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Rozrolimupab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Rozrolimupab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Rozrolimupab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Rozrolimupab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Rozrolimupab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Rozrolimupab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Rozrolimupab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Rozrolimupab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Rozrolimupab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Rozrolimupab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Girentuximab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Obiltoxaximab. |
| XTL-001 | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with XTL-001. |
| NAV 1800 | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with NAV 1800. |
| Briakinumab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Briakinumab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Otelixizumab. |
| AMG 108 | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with AMG 108. |
| Iratumumab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Iratumumab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Enokizumab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Ramucirumab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Farletuzumab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Veltuzumab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Ustekinumab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Trastuzumab emtansine. |
| PRO-542 | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with PRO-542. |
| TNX-901 | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with TNX-901. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Inotuzumab ozogamicin. |
| RI 624 | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with RI 624. |
| Stamulumab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with MYO-029. |
| CT-011 | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with CT-011. |
| Leronlimab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Leronlimab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Glembatumumab vedotin. |
| Olaratumab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Olaratumab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with IPH 2101. |
| TB-402 | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with TB-402. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Caplacizumab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with IMC-1C11. |
| Eldelumab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Eldelumab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Lumiliximab. |
| Canakinumab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Canakinumab. |